ampakine


Also found in: Wikipedia.

ampakine

An AMPA-type glutamine receptor agonist (e.g., CX516) which facilitates synaptic transmission by binding to glutamate and enhancing long-term potentiation, a critical component in memory. Amakines enhance the activity of AMPA receptor-rich neurons by amplifying neural signals, and are reported to improve memory in early trials in Alzheimer’s disease and schizophrenia.

ampakine

Neuropharmacology Any compound that facilitates synaptic transmission by binding to glutamate and enhance long-term potentiation, a critical component in long term memory, by enhancing the activity of AMPA receptor-rich neurons which enhance AMPA receptor activity by amplifying neural signals generated by glutamate binding; ampakines improve memory in early trials in Alzheimer's disease, schizophrenia See AMPA receptor, Long-term potentiation.
Mentioned in ?
References in periodicals archive ?
One ampakine is currently being tested in people with Alzheimer's disease.
Roger Stoll, CEO of Cortex Pharmaceuticals, a neuroscience company focused on innovative drug therapy including their leading ampakine compound, CX717 which targets various neurological and psychiatric disorders.
Increased net losses in the current year periods reflect development expenses for the AMPAKINE(R) compound, CX717 and increased preclinical research and development of the AMPAKINE technology.
Unfortunately, the first generation drug faltered in clinical trials but the firm is moving ahead with a more potent ampakine, CX717.
These AMPAKINE compounds are a very interesting class of molecules," said Vincent F.
Gary Lynch of the University of California, Irvine, said Sunday the drug called ampakine CX-516 accelerates signals between brain cells and appears to sharpen the memory significantly.
Specifically, these new AMPAKINE patents cover a series of compounds including the lead preclinical compounds, CX2007 and CX2076.
Cortex Pharmaceuticals is testing and developing a second-generation class of pharmaceuticals classified as ampakine compounds.
Cortex's Ampakine family of compounds, numbering approximately 300 to date, target nerve cell connections that exist only in the brain.
The Company is not entitled to any royalties or further payments from Servier's development and commercialization of CX1632, other than reimbursements for certain royalties and milestone payments to the University of California paid by Cortex, but Cortex retains all rights for its remaining AMPAKINE technology on a worldwide basis.
The AMPAKINE compounds target and enhance the function of complexes in the brain called the AMPA-type receptors, which are thought to play a role in memory formation.
The MOU also provides Samyang with rights of negotiation to expand its territory into other South East Asian countries, excluding Japan, Taiwan and China, and to include rights to the high impact AMPAKINE CX1846 as a potential treatment for neurodegenerative diseases.